Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)

NCT00615927 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma
Gliosarcoma

Interventions

DRUG: Imatinib Mesylate & Hydroxyurea

Sponsor

Duke University

Collaborators

[object Object]